Pulse Biosciences, Inc.’s Post

View organization page for Pulse Biosciences, Inc., graphic

8,047 followers

Atrial fibrillation is on the rise, with over 12 million expected annual cases in the US by 2030.¹ Reducing this burden, on patients and healthcare systems alike, requires innovation beyond today’s standards of care. Review the risk factors below and learn how advancements like our CellFX® Nanosecond Pulsed Field Ablation (nsPFA™) technology are designed to offer a potentially safer, more effective solution: https://lnkd.in/gTTxduvQ Caution: Investigational Device. #AtrialFibrillation #nsPFA #PulsedFieldAblation

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics